NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (NEW SHARP PHARMACEUTICALS) FORECASTS THAT THE GROUP'S NET LOSS FOR THE FISCAL YEAR TO DECEMBER 31, 2023 WILL NOT EXCEED HKD3000 MILLION, A SIGNIFICANT DECREASE FROM HK$7790 MILLION IN 2022. The improvement was primarily attributable to unrecognized share-based payment expenses for the year, as well as a significant reduction in inventory impairment losses. The company notes that the financial data for 2023 has not yet been audited and the final data may be adjusted without review or review by auditors. The company will publish full financial results by the end of March 2024.

NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (NEW SHARP PHARMACEUTICALS) FORECASTS THAT THE GROUP'S NET LOSS FOR THE FISCAL YEAR TO DECEMBER 31, 2023 WILL NOT EXCEED HKD3000 MILLION, A SIGNIFICANT DECREASE FROM HK$7790 MILLION IN 2022. The improvement was primarily attributable to unrecognized share-based payment expenses for the year, as well as a significant reduction in inventory impairment losses. The company notes that the financial data for 2023 has not yet been audited and the final data may be adjusted without review or review by auditors. The company will publish full financial results by the end of March 2024.